Patients with one of four subtypes of non-Hodgkin’s lymphoma have shown a response to treatment with a CD-19 antibody called MOR208 which was administered as a monotherapy. Data from the Phase 2a study also showed the drug was well tolerated, according to the developer MorphoSys AG.
